David Noakes, a director of Immuno Biotech, a Guernsey company, was jailed after pleading guilty to four charges of manufacturing and selling an unlicensed medicine, and one count of money laundering.
The prosecution followed a three-year investigation by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA), which claimed Noakes had made £10 million from the sale of GcMAF between 2012 and 2015, when regulators raided the company's manufacturing plant in Cambridgeshire.
In a statement, the MHRA said there was no scientific evidence to support Noakes's claims that GcMAF was a 'miracle cure' for cancer, HIV and autism.
But Judge Nicholas Lorraine-Smith said that "it is not GcMAF that is on trial." He acknowledged that Noakes 'firmly' believed GcMAF had helped many people but had shown "a reckless disregard for the regulatory regime."
GcMAF—globulin component macrophage activating factor—is a protein that is naturally produced by the body and plays an important role in the healthy functioning of the immune system, and especially in activating macrophages, the white blood cells that protect against cancerous cells, bacteria and 'foreign substances.'
People who are immuno-compromised have low levels of the protein, and are more susceptible to cancer, multiple sclerosis and other systemic conditions, manufacturers have claimed.
In the US, Dr Jeff Bradstreet used GcMAF to treat more than 11,000 patients until his offices were raided by the Food and Drug Administration (FDA) in 2015. Facing a long jail sentence, Dr Bradstreet fled, and his body was found hours later, floating in a river with gunshot wounds to the chest. Police reported the incident as suicide, but Dr Bradstreet's family has continued to investigate his death.